NCT03452592View on ClinicalTrials.gov

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

PHASE2TerminatedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

April 30, 2018

Primary Completion Date

April 21, 2021

Study Completion Date

March 14, 2024

Conditions
Advanced NSCLC Patients With T790M
Interventions
DRUG

Alflutinib

Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg

Trial Locations (1)

Unknown

cancer hospital Chinese academy of medical sciences, Beijing

Sponsors
All Listed Sponsors
lead

Allist Pharmaceuticals, Inc.

INDUSTRY